Anixa Biosciences, Inc.
ANIX
$3.09
-$0.17-5.22%
NASDAQ
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.56% | -17.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.06% | -18.88% | |||
| Operating Income | -18.06% | 18.88% | |||
| Income Before Tax | -19.39% | 18.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.39% | 18.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 22.73% | -4.35% | |||
| Net Income | -19.35% | 19.07% | |||
| EBIT | -18.06% | 18.88% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -17.70% | 19.75% | |||
| Normalized Basic EPS | -17.59% | 19.85% | |||
| EPS Diluted | -17.70% | 19.75% | |||
| Normalized Diluted EPS | -17.59% | 19.85% | |||
| Average Basic Shares Outstanding | 1.42% | 0.85% | |||
| Average Diluted Shares Outstanding | 1.42% | 0.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||